Probiotic and Colchicine in COVID-19
COVID-19
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring Probiotics, Colchicine, COVID-19, Ain Shams University.
Eligibility Criteria
Inclusion Criteria: Participants aged (18-60) years with confirmed criteria of COVID-19 infection. Mild cases: Participants have mild symptoms such as anosmia, loss of taste, fever or respiratory tract symptoms, gastrointestinal symptoms, etc. and free chest imaging. Moderate Cases: Participants have symptoms such as fever, respiratory tract symptoms, gastrointestinal symptoms, etc. and pneumonia manifestations can be seen in chest imaging Exclusion Criteria: Age below 18 years or above 60 years. Pregnancy, lactation. Any co-morbidities e.g. (DM, hypertension, Asthma) Participants receiving immunosuppressive or chemotherapy drugs. Active malignancy Severe confirmed cases, fulfilling any of the following criteria: Respiratory rate more than 30/min. Blood oxygen saturation of less than 93%. Lung infiltrates >50% of the lung fields or rapid progression within 24-48 hours. Participants need respiratory support e.g. high flow oxygen, non-invasive or invasive mechanical ventilation. Critical cases defined as: occurrence of respiratory failure requiring mechanical ventilation; Presence of shock; other organ failure that requires monitoring and treatment in the ICU
Sites / Locations
- Ain Shams University
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
Group A (Colchicine group)
Group B (Probiotic group)
Group C (Control group)
consisted of COVID-19 participants with mild to moderate disease who received the recommended course of care in accordance with the protocol established by the Egyptian Supreme Council of University Hospitals, as well as Colchicine tablets (0.5 mg) three times per day for three days and subsequently twice per day for four days
consisted of COVID-19 participants with mild and moderate COVID-19 severity got probiotics in the form of oral sachets once daily for two weeks in addition to protocol prescribed by the Egyptian Supreme Council of University Hospitals.
consisted of COVID-19 participants with mild and moderate severity who received the recommended course of care in accordance with the protocol established by the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks, and necessary protocol of management based on case assessment and severity).